Regulation of GTPase activity of LRRK2 and its implication in Parkinson?s disease

LRRK2 GTPase 活性的调控及其在帕金森病中的意义

基本信息

  • 批准号:
    7469742
  • 负责人:
  • 金额:
    $ 16.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Leucine-rich repeat kinase 2 (LRRK2) is a newly identified gene whose mutations are associated with late onset pathogenesis of Parkinson's disease (PD) and have unprecedented prevalence in both familial and sporadic PD. Thus, LRRK2 provides a unique opportunity for understanding the pathogenesis of PD. Despite this, little is currently known about the function of the LRRK2 or its role in PD pathogenesis. The long-term goal of this program is to unveil the molecular mechanisms by which mutant LRRK2 is involved in the pathogenesis of PD. Our specific approach is to identify interacting proteins that define and regulate the GTPase function of LRRK2. LRRK2 contains multiple catalytic and protein interaction domains which may be involved in integrating signaling pathways crucial for neuronal function. The Roc domain of LRRK2 is reported to have GTPase activity that may intra- molecularly regulates the kinase activity of LRRK2. Using this domain and its associated COR domain as bait, we have recently identified specific interactions of two known signaling proteins with LRRK2, a RacGAP and an antioxidant protein. The interaction with a RacGAP may help to define the function of the Roc domain as well as its regulation. On the other hand, the interaction of LRRK2 with an antioxidant protein may provide a molecular link for a role of LRRK2 in neurodegenerative processes such as oxidative stress. Therefore, we hypothesize that LRRK2 has Rac-like GTPase activity that regulates downstream effectors, such as antioxidant proteins, to play a role in neuronal maintenance and survival. The following specific aims are designed to test this hypothesis: (1) To examine whether LRRK2 has Rac-like GTPase activity that is regulated by a known interacting RacGAP. We will further characterize the specificity of the interaction and investigate if the Rac-like GTPase activity of the Roc domain is regulated by the GAP. We will then determine how the PD pathogenic mutations interfere with this regulation. Finally we will examine if the regulation of LRRK2 GTPase activity regulates its kinase activity. (2) To determine whether LRRK2 regulates an identified interacting antioxidant protein to effect neuronal survival. We will first characterize the specificity of the interaction and examine whether Prx2 is phosphorylated by LRRK2. We will then investigate how the function of the antioxidant protein is regulated by LRRK2 through this interaction. Our proposed studies will not only examine the normal regulation and function of LRRK2 in neuronal signaling but also the role of its PD associated mutants in neuronal pathogenesis. PUBLIC HEALTH RELEVANCE: As a newly identified PD associated gene, leucine-rich repeat kinase 2 (LRRK2) shows striking linkage with both familial and sporadic PD and is associated with typical late-onset pathogenesis. Therefore, our proposed studies on the LRRK2 interacting proteins will not only examine the normal regulation and function of LRRK2 in neuronal signaling but also provide insight into the mechanisms by which the pathogenic mutants are involved in PD pathogenesis. Furthermore, functional understanding of LRRK2 interactions with its signaling partners will likely reveal novel therapeutic targets, in addition to LRRK2 itself, for the treatment of PD.
描述(由申请人提供):富含亮氨酸重复序列激酶2(LRRK2)是一种新发现的基因,其突变与帕金森病(PD)的晚发型发病机制相关,在家族性和散发性PD中的患病率前所未有。因此,LRRK2为理解PD的发病机制提供了独特的机会。尽管如此,目前对LRRK2的功能或其在PD发病机制中的作用知之甚少。该项目的长期目标是揭示突变型LRRK2参与PD发病机制的分子机制。我们的具体方法是鉴定定义和调节LRRK2的GT3功能的相互作用蛋白。LRRK2包含多个催化和蛋白质相互作用结构域,其可能参与整合对神经元功能至关重要的信号通路。据报道,LRRK2的Roc结构域具有GTP酶活性,其可以在分子内调节LRRK2的激酶活性。使用这个结构域及其相关的COR结构域作为诱饵,我们最近已经确定了两个已知的信号蛋白与LRRK2,RacGAP和抗氧化蛋白的特异性相互作用。与RacGAP的相互作用可能有助于定义Roc结构域的功能及其调节。另一方面,LRRK2与抗氧化蛋白的相互作用可能为LRRK2在神经退行性过程如氧化应激中的作用提供分子联系。因此,我们假设LRRK2具有Rac样GT3活性,其调节下游效应物,如抗氧化蛋白,在神经元维持和存活中发挥作用。以下具体目的旨在检验这一假设:(1)检查LRRK2是否具有由已知相互作用的RacGAP调节的Rac样GT3活性。我们将进一步表征相互作用的特异性,并研究Roc结构域的Rac样GTdR活性是否受GAP调控。然后,我们将确定PD致病突变如何干扰这种调节。最后,我们将检查LRRK2 GT3活性的调节是否调节其激酶活性。(2)确定LRRK2是否调节已鉴定的相互作用的抗氧化蛋白以影响神经元存活。我们将首先表征相互作用的特异性,并检查Prx2是否被LRRK2磷酸化。然后,我们将研究抗氧化蛋白的功能如何通过这种相互作用由LRRK2调节。我们提出的研究不仅将检查LRRK2在神经元信号传导中的正常调节和功能,还将检查其PD相关突变体在神经元发病机制中的作用。 公共卫生关系:富含亮氨酸重复序列激酶2(LRRK2)是新近发现的PD相关基因,与家族性和散发性PD均存在显著关联,并与典型的晚发型发病机制相关。因此,我们对LRRK2相互作用蛋白的研究不仅将研究LRRK2在神经元信号传导中的正常调节和功能,而且还将深入了解致病突变体参与PD发病机制的机制。此外,LRRK2与其信号传导伙伴相互作用的功能理解将可能揭示除了LRRK2本身之外的新的治疗靶点,用于治疗PD。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yongjian Liu其他文献

Yongjian Liu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yongjian Liu', 18)}}的其他基金

Targeted Molecular Probes for Atherosclerosis Imaging and Therapy
用于动脉粥样硬化成像和治疗的靶向分子探针
  • 批准号:
    10554272
  • 财政年份:
    2019
  • 资助金额:
    $ 16.49万
  • 项目类别:
Targeted Molecular Probes for Atherosclerosis Imaging and Therapy
用于动脉粥样硬化成像和治疗的靶向分子探针
  • 批准号:
    10330956
  • 财政年份:
    2019
  • 资助金额:
    $ 16.49万
  • 项目类别:
Targeted Molecular Probes for Atherosclerosis Imaging and Therapy
用于动脉粥样硬化成像和治疗的靶向分子探针
  • 批准号:
    10088464
  • 财政年份:
    2019
  • 资助金额:
    $ 16.49万
  • 项目类别:
Imaging of Chemokine Receptors
趋化因子受体成像
  • 批准号:
    10480878
  • 财政年份:
    2018
  • 资助金额:
    $ 16.49万
  • 项目类别:
Imaging of Chemokine Receptors
趋化因子受体成像
  • 批准号:
    10254233
  • 财政年份:
    2018
  • 资助金额:
    $ 16.49万
  • 项目类别:
Imaging macrophage subset dynamics in inflammation
炎症中巨噬细胞亚群动态成像
  • 批准号:
    10715915
  • 财政年份:
    2018
  • 资助金额:
    $ 16.49万
  • 项目类别:
CHEMOKINE RECEPTORS BASED NANOAGENTS IMAGING ATHEROSCLEROSIS
基于趋化因子受体的动脉粥样硬化成像纳米制剂
  • 批准号:
    9188466
  • 财政年份:
    2014
  • 资助金额:
    $ 16.49万
  • 项目类别:
MEMBRANE TRAFFICKING OF A VESICULAR MONOAMINE TRANSPORTER
囊泡单胺转运蛋白的膜贩运
  • 批准号:
    7181620
  • 财政年份:
    2004
  • 资助金额:
    $ 16.49万
  • 项目类别:
Membrane Trafficking of a Vesicular Monoamine Transporter
囊泡单胺转运蛋白的膜运输
  • 批准号:
    6980056
  • 财政年份:
    2004
  • 资助金额:
    $ 16.49万
  • 项目类别:
Membrane Trafficking of Vesicular Monoamine Transporter
囊泡单胺转运蛋白的膜运输
  • 批准号:
    6723679
  • 财政年份:
    2001
  • 资助金额:
    $ 16.49万
  • 项目类别:

相似国自然基金

骨髓基质干细胞移植对AD(Alzheimer disease)小鼠海马及额叶神经细胞死亡干预的实验研究
  • 批准号:
    81301089
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 批准年份:
    2010
  • 资助金额:
    26.0 万元
  • 项目类别:
    地区科学基金项目
Batten Disease (BD)神经元退化病理机制的研究
  • 批准号:
    30900802
  • 批准年份:
    2009
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
  • 批准号:
    30960334
  • 批准年份:
    2009
  • 资助金额:
    22.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Patient Lifestyle and Disease Data Interactium (PaLaDIn)
患者生活方式和疾病数据交互 (PaLaDIn)
  • 批准号:
    10103989
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    EU-Funded
Patient Lifestyle and Disease Data Interactium (PaLaDIn)
患者生活方式和疾病数据交互 (PaLaDIn)
  • 批准号:
    10105921
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    EU-Funded
Development of digital diagnostics services for Parkinson’s disease
开发帕金森病数字诊断服务
  • 批准号:
    10086932
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Collaborative R&D
Discovering early biomarkers of Alzheimer's disease using genetic and physics-informed networks
利用遗传和物理信息网络发现阿尔茨海默病的早期生物标志物
  • 批准号:
    2904538
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Studentship
Development and Translation Mass Spectrometry Methods to Determine BioMarkers for Parkinson's Disease and Comorbidities
确定帕金森病和合并症生物标志物的质谱方法的开发和转化
  • 批准号:
    2907463
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Studentship
Pulmonary rehabilitation delivered in low resource settings for people with chronic respiratory disease: a 3-arm assessor-blind implementation trial
在资源匮乏的环境中为慢性呼吸道疾病患者提供肺康复:一项三臂评估者盲法实施试验
  • 批准号:
    MR/Y004809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Research Grant
The gut-kidney-heart axis as a driver of cardiovascular disease progression
肠-肾-心轴是心血管疾病进展的驱动因素
  • 批准号:
    MR/Y010051/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Fellowship
Human enteric nervous system progenitor dynamics during development and disease
人类肠神经系统祖细胞在发育和疾病过程中的动态
  • 批准号:
    MR/Y013476/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Research Grant
Anti-infective therapeutics and predictive modelling to tackle Staphylococcus aureus disease
应对金黄色葡萄球菌疾病的抗感染疗法和预测模型
  • 批准号:
    EP/X022935/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Fellowship
RII Track-4:NSF: Physics-Informed Machine Learning with Organ-on-a-Chip Data for an In-Depth Understanding of Disease Progression and Drug Delivery Dynamics
RII Track-4:NSF:利用器官芯片数据进行物理信息机器学习,深入了解疾病进展和药物输送动力学
  • 批准号:
    2327473
  • 财政年份:
    2024
  • 资助金额:
    $ 16.49万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了